Literature DB >> 11319230

Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.

J W Chang1, D E Mechling, H P Bächinger, G G Burrows.   

Abstract

Major histocompatibility complex (MHC) class II molecules are membrane-anchored heterodimers on the surface of antigen-presenting cells that bind the T cell receptor, initiating a cascade of interactions that results in antigen-specific activation of clonal populations of T cells. Susceptibility to multiple sclerosis is associated with certain MHC class II haplotypes, including human leukocyte antigen (HLA) DR2. Two DRB chains, DRB5*0101 and DRB1*1501, are co-expressed in the HLA-DR2 haplotype, resulting in the formation of two functional cell surface heterodimers, HLA-DR2a (DRA*0101, DRB5*0101) and HLA-DR2b (DRA*0101, DRB1*1501). Both isotypes can present an immunodominant peptide of myelin basic protein (MBP-(84-102)) to MBP-specific T cells from multiple sclerosis patients. We have previously demonstrated that the peptide binding/T cell recognition domains of rat MHC class II (alpha1 and beta1 domains) could be expressed as a single exon for structural and functional characterization; Burrows, G. G., Chang, J. W., Bächinger, H.-P., Bourdette, D. N., Wegmann, K. W., Offner, H., and Vandenbark A. A. (1999) Protein Eng. 12, 771-778; Burrows, G. G., Adlard, K. L., Bebo, B. F., Jr., Chang, J. W., Tenditnyy, K., Vandenbark, A. A., and Offner, H. (2000) J. Immunol. 164, 6366-6371). Single-chain human recombinant T cell receptor ligands (RTLs) of approximately 200 amino acid residues derived from HLA-DR2b were designed using the same principles and have been produced in Escherichia coli with and without amino-terminal extensions containing antigenic peptides. Structural characterization using circular dichroism predicted that these molecules retained the antiparallel beta-sheet platform and antiparallel alpha-helices observed in the native HLA-DR2 heterodimer. The proteins exhibited a cooperative two-state thermal unfolding transition, and DR2-derived RTLs with a covalently linked MBP peptide (MBP-(85-99)) showed increased stability to thermal unfolding relative to the empty DR2-derived RTLs. These novel molecules represent a new class of small soluble ligands for modulating the behavior of T cells and provide a platform technology for developing potent and selective human diagnostic and therapeutic agents for treatment of autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11319230     DOI: 10.1074/jbc.M101808200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.

Authors:  Grazyna Adamus; Lori Brown; Shayne Andrew; Roberto Meza-Romero; Gregory G Burrows; Arthur A Vandenbark
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

Review 2.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

Review 3.  Class II major histocompatibility complex tetramer staining: progress, problems, and prospects.

Authors:  Sabrina S Vollers; Lawrence J Stern
Journal:  Immunology       Date:  2008-03       Impact factor: 7.397

Review 4.  Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.

Authors:  Halina Offner; Sushmita Sinha; Chunhe Wang; Gregory G Burrows; Arthur A Vandenbark
Journal:  Rev Neurosci       Date:  2008       Impact factor: 4.353

5.  Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis.

Authors:  Gregory G Burrows; Wouter Van't Hof; Laura F Newell; Ashok Reddy; Phillip A Wilmarth; Larry L David; Amy Raber; Annelies Bogaerts; Jef Pinxteren; Robert J Deans; Richard T Maziarz
Journal:  Stem Cells Transl Med       Date:  2013-08-27       Impact factor: 6.940

6.  Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.

Authors:  Wenbin Zhu; Nicole L Libal; Amanda Casper; Sheetal Bodhankar; Halina Offner; Nabil J Alkayed
Journal:  Transl Stroke Res       Date:  2014-06-24       Impact factor: 6.829

7.  Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity.

Authors:  Jianya Y Huan; Roberto Meza-Romero; Jeffery L Mooney; Yuan K Chou; David M Edwards; Cathleen Rich; Jason M Link; Arthur A Vandenbark; Dennis N Bourdette; Hans-Peter Bächinger; Gregory G Burrows
Journal:  J Chem Technol Biotechnol       Date:  2004-10-12       Impact factor: 3.174

8.  Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.

Authors:  Chunhe Wang; Bruce G Gold; Laurie J Kaler; Xiaolin Yu; Michael E Afentoulis; Gregory G Burrows; Arthur A Vandenbark; Dennis N Bourdette; Halina Offner
Journal:  J Neurochem       Date:  2006-08-03       Impact factor: 5.372

9.  Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis.

Authors:  Gregory G Burrows; Roberto Meza-Romero; Jianya Huan; Sushmita Sinha; Jeffrey L Mooney; Arthur A Vandenbark; Halina Offner
Journal:  Metab Brain Dis       Date:  2012-03-07       Impact factor: 3.584

10.  Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG.

Authors:  Sushmita Sinha; Sandhya Subramanian; Ashley Emerson-Webber; Maren Lindner; Gregory G Burrows; Marjorie Grafe; Christopher Linington; Arthur A Vandenbark; Claude C A Bernard; Halina Offner
Journal:  J Neuroimmune Pharmacol       Date:  2009-09-30       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.